COMPANY PROFILE / iPS CELLS & REGENERATIVE MEDICINE
Caribou Biosciences
A company that edits healthy donors' cells with CRISPR to make an "off-the-shelf CAR-T", and is now preparing a Phase 3 trial
Caribou Biosciences is not an iPS cell company but a company that builds cell therapies through genome editing. Using its own CRISPR technology, "chRDNA", it edits T cells from healthy donors at several sites to make CAR-T cells (allogeneic, from a donor) that can be manufactured in advance and kept ready, and it is developing them as candidate treatments for blood cancers. In April 2025 it narrowed its pipeline to two programmes and cut its workforce by about 32%. In May 2026 it announced that it had agreed the design of a Phase 3 trial of its lead programme, vispa-cel, with the FDA, and it held US$113.8 million in cash and investments at the end of June 2026. This profile sets out what it is developing, whom it works with, how far it has got and what remains unconfirmed, using only the company's statutory filings and ClinicalTrials.gov.
- Caribou Biosciences in 30 seconds, and where it stands in iPS cells and regenerative medicine
- The logo and how the name is written
- Where the company sits in iPS cells and regenerative medicine
- Scale
- Resources committed to iPS cells and regenerative medicine
- Track record so far
- Plans ahead
- What the company is aiming for in iPS cells and regenerative medicine
- Partnership map for iPS cells and regenerative medicine
- Technology, products and services on offer
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Caribou Biosciences in 30 seconds, and where it stands in iPS cells and regenerative medicine
California, U.S.Leases about 71,735 square feet of laboratory and office space
Cell therapy (secondary)Does not use iPS cells (not mentioned in the 10-K)
(off-the-shelf)T cells from healthy donors, edited with CRISPR chRDNA
Cell therapy companies in this field build their products very differently depending on whether they use the patient's own cells (autologous) or someone else's cells (allogeneic). Caribou is in the second group: it aims to make many doses in advance from a single manufacturing run, using T cells from healthy donors Sourced. Allogeneic cells can be attacked in the patient's body as foreign, or can in turn attack the patient's tissues, so the company has designed its cells to suppress both problems by editing several genes with CRISPR. All the results quoted here come from small Phase 1 trials with no comparison group and are no guarantee of a therapeutic effect.
2. The logo and how the name is written
A note on names: the legal entity is Caribou Biosciences, Inc., a Delaware corporation. "vispa-cel" is the new name for CB-010 and is read "vis-pa-sel". It is a development code name, not the name of an approved drug. On the foundational CRISPR patents, the company licenses a family of core patents from the University of California and the University of Vienna. According to the 10-K, it holds no licence from one of the other co-owners of the same CRISPR patent family (Dr Charpentier).
Official site: https://www.cariboubio.com/3. Where the company sits in iPS cells and regenerative medicine
With allogeneic CAR-T, two problems must both be held in check: graft-versus-host disease (GvHD), in which the donor's cells attack the patient's tissues, and rejection, in which the patient's immune system eliminates the infused cells. Caribou's design suppresses GvHD by disrupting the gene for the T-cell receptor (TCR), and suppresses rejection by removing the B2M gene and introducing an HLA-E fusion molecule Sourced. The ideas overlap with our explainers on MHC and universal donors, CAR-T cells, autologous versus allogeneic therapy, and cytokine release syndrome.
4. Scale
This is a clinical-stage company, so the figures to watch are R&D spending and cash on hand rather than sales Sourced. Amounts are in US dollars.
| Metric (US$ thousand) | FY2024 (year to December 2024) | FY2025 (year to December 2025) | January to June 2026 |
|---|---|---|---|
| Revenue (licence and collaboration income) | 9,994 | 11,159 | 3,896 |
| Research and development expense | 130,153 | 109,439 | 39,553 |
| Net loss | (149,105) | (148,125) | (49,367) |
| Capital expenditure (purchase of property and equipment) | 4,880 | 1,359 | – |
| Item | Detail | As of |
|---|---|---|
| Cash and investments (cash and marketable securities) | US$142.8 million | 31 December 2025 |
| Cash and investments (cash and marketable securities) | US$113.8 million | 30 June 2026 |
| Funding outlook (company) | Expected to fund operations for at least 12 months from the filing date. Fully funding the Phase 3 trial, however, would require additional capital | 10-Q |
| Employees | 97 | 27 February 2026 |
| Accumulated deficit | US$645.9 million | 30 June 2026 |
| Net capital raised since founding | US$849.0 million | Through 31 December 2025 |
Revenue comes from licensing and similar income, and there are no product sales. The company itself says that additional capital will be needed to fully fund the Phase 3 trial, ANTLER-3 Sourced. In the first half of 2026 it raised about US$20.1 million through an at-the-market (ATM) share offering.
5. Resources committed to iPS cells and regenerative medicine
We give amounts only where they have been disclosed, and write "not confirmed" where they have not.
| Type of resource | Detail | Category |
|---|---|---|
| People | 97 employees (February 2026). 47 people (about 32%) were cut in April 2025 | Sourced |
| Research site | About 71,735 square feet in Berkeley, California. The leases expire in July 2032 and March 2033 (each extendable by five years) | Sourced |
| Money: R&D expense | US$109.4 million in FY2025 (down US$20.7 million on the prior year). US$39.6 million in January to June 2026 | Sourced |
| Manufacturing | No manufacturing facility of its own. Five contract manufacturing organisations (CMOs) supply guide RNA, Cas9 and Cas12a proteins, plasmids, AAV6 vectors and similar materials, and a different CMO makes the CAR-T cells themselves. An in-house plant in future is only something it "may consider" | Sourced |
| In-licensing from outside | Core CRISPR-Cas9 patent family licensed from the University of California and the University of Vienna. A BCMA-targeting scFv and patents bought from ProMab (January 2020; upfront payment of US$0.4 million at signing) | Sourced |
| Outside investments and acquisitions | The 10-K lists no investments in or acquisitions of start-ups. Proceeds from selling shares of Intellia are one of its sources of funds | Sourced |
| Investment from outside | In June 2023 Pfizer bought 4,690,431 shares for about US$25.0 million (use limited to BCMA-targeting programmes such as CB-011) | Sourced |
| Public funding and grants | The 10-K lists no government subsidies or public grants | Not confirmed |
| Universities and research institutions | University of California and University of Vienna (patent licence). The licence with Memorial Sloan Kettering Cancer Center ended in August 2025 | Sourced |
According to the 10-K, the company's therapy rests on four inputs and steps: guide RNA (chRDNA is a hybrid in which part of the RNA is replaced with DNA), the Cas enzyme, the virus used to insert the gene (such as an AAV6 vector), and T cells from donors. The company itself lists as a risk that its virus supply comes only from CMOs outside the U.S. that the FDA has not inspected Sourced. In an allogeneic, off-the-shelf model, many doses are made from one lot, so the reproducibility of culture, cryopreservation and post-thaw viability translates directly into stability of supply Not yet confirmed. The company has not disclosed its control values for these, so this paragraph is a general discussion of materials and processes.
6. Track record so far
The timeline is limited to what we could confirm in statutory filings and ClinicalTrials.gov.
| When | What happened | Why it matters |
|---|---|---|
| 2011 | Founded; the founders include Dr Jennifer Doudna. Dr Rachel Haurwitz has been CEO since the founding | One of the developers of CRISPR-Cas9 was involved in the founding |
| 2013 to 2015 | Licensed the core CRISPR-Cas9 patent family from the University of California and the University of Vienna. Cross-licensed patents with Intellia and with Pioneer (now Corteva Agriscience) | Built a position from which to use the core patents widely |
| December 2020 | Took ownership of the chRDNA patent family from Pioneer | chRDNA technology became its own patented technology |
| May 2021 | Started the Phase 1 trial ANTLER of vispa-cel (formerly CB-010) (start date on ClinicalTrials.gov) | The first trial of allogeneic CAR-T in humans |
| February 2023 | Started the Phase 1 trial CaMMouflage of CB-011 | BCMA-targeting multiple myeloma |
| June 2023 | Pfizer invested US$25.0 million | Development funds for BCMA-targeting programmes |
| February 2024 | Started the Phase 1 trial AMpLify of CB-012 (targets CLL-1) | For acute myeloid leukaemia |
| 24 April 2025 | Reprioritised the business. GALLOP (lupus) was stopped before any patient was dosed, CB-012 was discontinued, preclinical research was stopped, and 47 positions were cut | Concentrated on two programmes: vispa-cel and CB-011 |
| August 2025 | Ended the licence with MSKCC (following the discontinuation of CB-012) | Gave up the rights tied to CB-012 |
| 3 November 2025 | Published data from the ANTLER confirmatory cohort and the CaMMouflage dose-escalation | The basis for the Phase 3 design |
| End of 2025 | Began the dose-expansion part of CaMMouflage | CB-011 moves to expansion cohorts |
| 7 May 2026 | Announced agreement with the FDA on the design of the Phase 3 trial ANTLER-3 | The framework for a trial to support a marketing application is now fixed |
| 11 June 2026 | Updated follow-up data for ANTLER and CaMMouflage. CB-011 received RMAT designation | Long-term follow-up figures refreshed |
7. Plans ahead
Outline of ANTLER-3 (10-Q): the trial will enrol about 250 patients with second-line large B-cell lymphoma who have not previously received a CD19-targeted therapy (CD19-naive) and who cannot have a transplant or autologous CAR-T, and compare vispa-cel (a single infusion) with a standard treatment chosen by the physician. The primary endpoint is progression-free survival (PFS), and patients on the standard-treatment side may cross over to vispa-cel after progression Not yet confirmed.
None of the following is stated in the primary sources Not yet confirmed.
The start date of ANTLER-3 and when results will come; the timing of a marketing application (BLA); plans for CB-011 beyond Phase 2; the expected price; the names of the commercial manufacturing contractors; and any plan to build its own plant. This article does not assert timing such as "approval will come at X".
8. What the company is aiming for in iPS cells and regenerative medicine
This chapter includes points the company does not state directly. We set out inferences that can be read from the primary sources, together with the grounds for each.
| What can be read from the sources | Primary-source basis | Category |
|---|---|---|
| A strategy of narrowing to two programmes and concentrating funds on the Phase 3 of vispa-cel | The April 2025 reprioritisation (three trials stopped), and the 10-Q's explicit statement that funding Phase 3 is a challenge | Inference |
| The company cannot carry Phase 3 to the end alone and is looking for partnerships or additional financing | The 10-K says it will "selectively pursue new strategic collaborations" and cites the need for more capital | Inference |
| The decisive question for allogeneic CAR-T is whether donor selection (younger donors, HLA matching) can raise efficacy | The company defines its optimal product profile as a donor under 30 years old with at least two HLA loci matched | Sourced |
| An investment restricted to particular programmes (Pfizer) shows interest in the BCMA programmes | Pfizer's investment may be used only for BCMA-targeting programmes. The term of the information-rights agreement runs to 29 June 2026 | Sourced |
| It is not turning to iPS cells and will keep to the route of editing donor-derived T cells | The 10-K contains no mention of using iPS cells or planning to | Inference |
The company's "optimal product profile" is one that uses T cells from a donor under 30 and matches the patient and donor at two or more of 12 HLA loci Sourced. For the 27 patients (second-line LBCL) who met these criteria, the company reports, as of the 6 March 2026 data cut, an overall response rate of 82%, a complete response rate of 67% and a median progression-free survival of 17.1 months (a single-arm Phase 1 with no comparison group). From this we read the company as seeing that allogeneic CAR-T is not "the same whoever's cells they are", and that results can depend on the combination of donor and patient. How far that profile can be maintained in Phase 3 will be the focus, but the outcome is not yet known Not yet confirmed.
9. Partnership map for iPS cells and regenerative medicine
10. Technology, products and services on offer
There are no products yet. What the company offers is its development candidates, which are edited allogeneic CAR-T cells, and the editing technology behind them Sourced.
| Programme | Target | Features | Stage (as of August 2026) |
|---|---|---|---|
| vispa-cel (formerly CB-010) | CD19-positive B-cell lymphoma (focus on second-line large B-cell lymphoma) | Allogeneic CAR-T with the PD-1 gene disrupted (the first such therapy to the company's knowledge) | Main data from the Phase 1 ANTLER (NCT04637763) published. Phase 3 ANTLER-3 planned. RMAT, Fast Track and orphan drug designations |
| CB-011 | BCMA-positive multiple myeloma | Suppresses rejection by removing B2M and introducing an HLA-E fusion molecule (the first such therapy to the company's knowledge) | Phase 1 CaMMouflage (NCT05722418). Dose expansion under way. RMAT, Fast Track and orphan drug designations |
| CB-012 | CLL-1-positive acute myeloid leukaemia | Allogeneic CAR-T | Phase 1 AMpLify (NCT06128044) discontinued |
| vispa-cel (lupus) | Systemic lupus erythematosus | Application to an autoimmune disease | GALLOP trial (NCT06752876) withdrawn (0 patients enrolled) |
Phase 1 data for vispa-cel (published by the company; all single-arm trials)
| Cohort | Patients | Overall response rate | Complete response rate | Follow-up |
|---|---|---|---|---|
| Confirmatory cohort (donor matched at 4 or more HLA loci) | 22 | 82% (18/22) | 64% (14/22) | Median 6.0 months (as of 29 September 2025) |
| Optimal-profile cohort (younger donor, 2 or more HLA loci matched) | 35 | 86% (30/35) | 63% (22/35) | Median 11.8 months (as of 29 September 2025) |
| Part of the optimal-profile cohort (second-line large-cell lymphoma) | 27 | 82% | 67% | Median progression-free survival 17.1 months (as of 6 March 2026) |
Safety (as of 2 September 2025): across all 84 patients, the most common adverse events were thrombocytopenia (62%), cytokine release syndrome (55%), anaemia (52%) and neutropenia (39%). In the confirmatory and optimal cohorts there were no reports of GvHD or of grade 3 or higher ICANS, and grade 3 or higher cytokine release syndrome occurred in 1%. On the other hand, prolonged cytopenia occurred in 28% of 80 patients, and there was one grade 5 (fatal) case of IEC-HS related to vispa-cel Sourced. In CB-011 (48 patients in dose escalation) there is one grade 5 haematological toxicity (ICAHT) related to CB-011. These figures are the company's own reports and do not show superiority over any other treatment.
chRDNA is a hybrid guide RNA in which part of the RNA is replaced with DNA, and the company says it gives fewer off-target edits than conventional CRISPR-Cas9 Sourced. Because edits are stacked at several sites, the materials that matter are the chemical purity of the synthesised guide, the quality of the Cas enzyme, and the titre and impurities of the viral vector. The company has not disclosed its control values for these, so this is a general discussion Not yet confirmed.
11. The risks this company carries
| Risk | Details | Category |
|---|---|---|
| Funding | Additional capital is needed to fully fund the Phase 3 trial ANTLER-3. Cash and investments were US$113.8 million at the end of June 2026 | Sourced |
| Strength of the clinical evidence | All figures come from single-arm Phase 1 trials. Phase 3 has not started, and results may change in a randomised controlled trial | Sourced |
| Safety | Prolonged cytopenia, infections, IEC-HS and others. One treatment-related death has been reported for each of vispa-cel and CB-011 | Sourced |
| Dependence on manufacturers | Relies on several CMOs. The virus supplier is outside the U.S. and has not been inspected by the FDA. Changing suppliers would require new studies and engagement with regulators | Sourced |
| Patents | The core CRISPR patents are co-owned by several institutions, and the company holds no licence from one of the co-owners. It could be affected by patent disputes | Sourced |
| Keeping its listing | The 10-K states that the company could be delisted if it fails to meet Nasdaq's continued listing requirements | Sourced |
| Competition | The 10-K says that the cell therapy and genome editing industries are intensely competitive and fast-moving. Autologous CAR-T and bispecific antibodies, among others, are ahead | Sourced |
| Downsizing of the business | Three trials were stopped and about 32% of staff were cut in 2025. Having few programmes magnifies the impact if one fails | Inference |
12. Glossary
- Allogeneic CAR-T
- Off-the-shelf CAR-T made from the T cells of healthy donors. It contrasts with the autologous type, which uses the patient's own cells.
- chRDNA
- Caribou's CRISPR technology. A hybrid guide RNA in which part of the RNA is replaced with DNA, said to improve the precision of editing.
- CAR-T cell
- A cell therapy in which T cells are given a receptor (CAR) that recognises a marker on cancer cells.
- GvHD
- Graft-versus-host disease. A complication in which donor cells attack the patient's tissues.
- HLA
- Human leukocyte antigen. The tissue "type" of donor and patient. The closer the match, the less likely rejection becomes.
- B2M / HLA-E
- Removing B2M makes class I HLA disappear from the cell surface. Adding an HLA-E fusion molecule makes the cells less likely to become an immune target.
- PD-1
- A molecule that acts as a brake causing T cells to tire (become exhausted). The company explains that disrupting it keeps CAR-T cells active.
- RMAT / Fast Track
- FDA designations for products aimed at serious diseases, which bring advantages in advice and review.
- CMO
- Contract manufacturing organisation, a company that makes pharmaceuticals under contract. Caribou has no plant of its own.
- AAV6
- A type of adeno-associated virus, used to introduce the CAR gene into cells.
- PFS
- Progression-free survival. The time after treatment during which the disease has not progressed and the patient is alive.
- ICANS / CRS
- Neurotoxicity (ICANS) and cytokine release syndrome (CRS), both seen with CAR-T.
13. References
- Caribou Biosciences Form 10-K for the year ended December 2025 (filed with the U.S. SEC on 5 March 2026). Business description, pipeline, clinical results, collaborations, finances, employees and manufacturing. https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm
- Caribou Biosciences Form 10-Q for the quarter ended 30 June 2026 (filed with the U.S. SEC on 13 August 2026). Agreement with the FDA on ANTLER-3, the June 2026 data update and the cash balance. https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/crbu-20260630.htm
- U.S. National Library of Medicine ClinicalTrials.gov NCT04637763 (vispa-cel [formerly CB-010], ANTLER trial, Phase 1). https://clinicaltrials.gov/study/NCT04637763
- U.S. National Library of Medicine ClinicalTrials.gov NCT05722418 (CB-011, CaMMouflage trial, Phase 1). https://clinicaltrials.gov/study/NCT05722418
- U.S. National Library of Medicine ClinicalTrials.gov NCT06128044 (CB-012, AMpLify trial, terminated). https://clinicaltrials.gov/study/NCT06128044
- U.S. National Library of Medicine ClinicalTrials.gov NCT06752876 (vispa-cel, GALLOP trial in systemic lupus erythematosus, withdrawn). https://clinicaltrials.gov/study/NCT06752876
- Caribou Biosciences Official website (used to check the logo and company overview). https://www.cariboubio.com/
14. Claim-to-source audit
| Claim in the article | Category | Source |
|---|---|---|
| Legal name (Caribou Biosciences, Inc.), head office location (Berkeley), Nasdaq listing, founded in 2011 | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| 97 employees (27 February 2026) and the April 2025 cut of 47 positions (about 32%) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Facilities (Berkeley, about 71,735 square feet) and lease expiry | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Revenue, R&D expense, net loss and capital expenditure (FY2024 and FY2025) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Revenue, R&D expense and net loss for January to June 2026, cash and investments of US$113.8 million, accumulated deficit | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/crbu-20260630.htm |
| Cash and investments of US$142.8 million at the end of December 2025, and US$849.0 million raised since founding | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Amount raised through the ATM offering in the first half of 2026 (about US$20.1 million) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/crbu-20260630.htm |
| No manufacturing facility of its own, reliance on five CMOs, and a virus supplier outside the U.S. not yet inspected by the FDA | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Licence of the core patents from UC and the University of Vienna, and no rights from one of the co-owners | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Cross-licensing of patents with Intellia and Corteva (Pioneer), and assignment of the chRDNA patents (December 2020) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Pfizer's investment (June 2023, US$25.0 million, 4,690,431 shares) and the term of the information-rights agreement (to 29 June 2026) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Purchase of the BCMA scFv from ProMab (January 2020) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| End of the licence with MSKCC (11 August 2025) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| The reprioritisation of 24 April 2025 (GALLOP and AMpLify stopped, preclinical research stopped) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| The ANTLER trial (Phase 1, started May 2021, primary endpoints) | Sourced | Reference 3 https://clinicaltrials.gov/study/NCT04637763 |
| The CaMMouflage trial (Phase 1, started February 2023, planned enrolment 50) | Sourced | Reference 4 https://clinicaltrials.gov/study/NCT05722418 |
| The AMpLify trial (CB-012) terminated and the GALLOP trial withdrawn (0 patients enrolled) | Sourced | References 5 and 6 https://clinicaltrials.gov/study/NCT06128044 https://clinicaltrials.gov/study/NCT06752876 |
| Results for the vispa-cel confirmatory and optimal-profile cohorts (published 3 November 2025) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| Results for the 27-patient subgroup (as of 6 March 2026), and the design of ANTLER-3 and agreement with the FDA (7 May 2026) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/crbu-20260630.htm |
| Results for the 48 CB-011 dose-escalation patients, the updated follow-up for the RDE (450x10^6 cells) cohort (as of 26 May 2026) and RMAT designation | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm https://www.sec.gov/Archives/edgar/data/1619856/000161985626000055/crbu-20260630.htm |
| RMAT, Fast Track and orphan drug designations for vispa-cel, and Fast Track and orphan drug designations for CB-011 | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| The design of the allogeneic CAR-T (TRAC disruption, PD-1 disruption, B2M removal with HLA-E fusion) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/crbu-20251231.htm |
| ANTLER-3 start date, timing of a marketing application, price and commercial manufacturing contractors | Not yet confirmed | Not stated in the primary sources. This article does not estimate them |
| Use of iPS cells | Not yet confirmed | Not mentioned in the 10-K. This article does not assert that there is none either |
| The reading that it has narrowed to two programmes and is concentrating funds on the Phase 3 of vispa-cel | Inference | This article's interpretation of the contents of the April 2025 reprioritisation |
| The reading that it is seeking partnerships or additional financing | Inference | This article's interpretation of the 10-K statements on funding and collaborations |
| The reading that it is not turning to iPS cells and will keep editing donor-derived T cells | Inference | This article's interpretation of the 10-K (no mention of iPS cells) |
| The risk that, after downsizing, having few programmes magnifies the impact of a failure | Inference | This article's own interpretation |
| Materials challenges around guide RNA, Cas enzyme and virus | Not yet confirmed | A general discussion in this article. The company has not disclosed its control values |
Last updated 1 October 2026 / Troy Technical
Every figure in this article comes from the statutory filings Caribou Biosciences has made with the U.S. Securities and Exchange Commission (SEC) and from ClinicalTrials.gov. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of the primary sources, not statements made by the company. This article does not recommend any particular treatment and is not medical advice.